Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eluxadoline→

Eluxadoline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
864821-90-9
PubChem CID
11250029
Molecular formula
C32H35N5O5
Molecular weight
569.6 g/mol
Drug class
mu-Opioid Receptor Agonist
Mechanism of action
Opioid mu-Receptor Agonists
Indications / reported uses
  • Irritable Bowel Syndrome

Identification source: PubChem record (CID 11250029). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eluxadoline Environmental Risk Assessment (ERA) (the Eluxadoline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.